What is HC Wainwright’s Estimate for AARD FY2027 Earnings?

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – Investment analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Aardvark Therapeutics in a report issued on Monday, July 20th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($1.98) per share for the year. HC Wainwright currently has a “Neutral” rating and a $6.00 target price on the stock. The consensus estimate for Aardvark Therapeutics’ current full-year earnings is ($3.46) per share.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.99) earnings per share (EPS) for the quarter.

Other research analysts have also issued research reports about the stock. BTIG Research downgraded shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Morgan Stanley reissued an “underweight” rating and set a $3.00 target price (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. Weiss Ratings upgraded shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. Finally, B. Riley Financial dropped their price target on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $16.30.

Aardvark Therapeutics Stock Performance

Shares of AARD opened at $5.53 on Tuesday. The company’s 50 day moving average price is $4.82 and its 200 day moving average price is $7.47. Aardvark Therapeutics has a 52 week low of $3.35 and a 52 week high of $17.94. The company has a market capitalization of $121.00 million, a PE ratio of -1.72 and a beta of 3.93.

Institutional Investors Weigh In On Aardvark Therapeutics

Large investors have recently made changes to their positions in the company. UBS Group AG grew its position in Aardvark Therapeutics by 5.4% in the third quarter. UBS Group AG now owns 54,728 shares of the company’s stock worth $727,000 after acquiring an additional 2,804 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Aardvark Therapeutics during the 2nd quarter valued at $42,000. Bank of America Corp DE raised its holdings in shares of Aardvark Therapeutics by 72.9% during the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after purchasing an additional 3,369 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aardvark Therapeutics in the 4th quarter valued at $47,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Aardvark Therapeutics in the 4th quarter valued at $56,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (ROR?). ROR? plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective ROR? inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.